HPV types 16 and 18 L1 capsid protein — Drug Target

All drugs that target HPV types 16 and 18 L1 capsid protein — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Bivalent HPV vaccine

Marketed (1)

• Cervarix®, GlaxoSmithKline · Cancer Prevention and Research Institute, Italy · Bivalent HPV vaccine · Oncology
  Cervarix is a bivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 16 and 18, preventing infection and cervical cancer development.